tiprankstipranks
ASKA Pharmaceutical Achieves Record Sales Amidst Rising R&D Costs
Company Announcements

ASKA Pharmaceutical Achieves Record Sales Amidst Rising R&D Costs

Story Highlights

Maximize Your Portfolio with Data Driven Insights:

  • Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
  • Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

An announcement from ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) is now available.

ASKA Pharmaceutical Holdings Co., Ltd. reported record-high sales in the third quarter of FY2024, driven by continued growth in its pharmaceutical and animal health businesses. Despite increased sales, operating profit remained stable year-over-year due to rising SG&A expenses linked to R&D progress, while the cost of sales ratio improved due to a favorable product mix.

More about ASKA Pharmaceutical Holdings Co., Ltd.

ASKA Pharmaceutical Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on the development and sale of pharmaceuticals and animal health products. The company is known for brand-name drugs such as RELUMINA and RIFXIMA.

YTD Price Performance: -6.29%

Average Trading Volume: 58,094

Technical Sentiment Consensus Rating: Hold

Current Market Cap: Yen55.89B

See more data about 4886 stock on TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App